The juggernaut continues -- and it was already doing well in prescribing trends for cervical cancer (oncologists had previously been using it off-label in this and other cancers, for at least five years). So this won't vastly increase the $25 billion a year franchise's take, but it will more deeply cement it, as the foundation of the gold standard therapy. Here's the latest:
. . .Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.
Today, Merck, with multiple facilities in eastern Pennsylvania and New Jersey, announced the first presentation of overall survival results from a pivotal Phase 3 trial, investigating Keytruda® (pembrolizumab), Merck’s anti-Programmed Cell Death Protein therapy, in combination with concurrent chemoradiotherapy (CRT) for newly diagnosed patients with high-risk locally advanced cervical cancer.
The study results of 1,020 patients showed the therapy reduced the risk of death by 33% versus concurrent CRT alone for these patients. The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies; no new safety signals were identified. . . .
Now you know -- onward with a smile -- as a glorious Fall mountain/lake vacation draws nigh. . . .
नमस्ते
No comments:
Post a Comment